The past year has seen a surge of investment into the Spatial Biology field with the recent Bruker acquisition of NanoString, and increased interest from biopharma into its potential to empower drug development, with many like AbbVie and GSK actively investing to update their labs to align with this.

It has never been a more exciting time to leverage Spatial Biology as the must-have tool for drug development, as more data emerges, and the different technologies undergo validation. However, the big questions of “how do you choose the right technology, how do you build the internal infrastructure to support this, and how can you build a business case to adopt the technology in a cost-effective and time-efficient way?” persists.

Making its timely return to Boston this October, the 2nd Spatial Biology for Drug Development Summit will enable you and your peers from the different functions to uncover practical, real-world case studies from biopharma to effectively apply spatial biology across drug discovery and development.

Join the only intimate, industry-focussed forum, where you can learn from the industry experts harnessing the different spatial technologies available to develop a gold standard and confidently empower your own drug development workflows to create better drugs.

Event link here.